You are currently viewing a new version of our website. To view the old version click .

Hemato, Volume 2, Issue 1

March 2021 - 9 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (9)

  • Article
  • Open Access
1 Citations
4,213 Views
13 Pages

Human Bone Marrow Mesenchymal Stromal Cell-Derived CXCL12, IL-6 and GDF-15 and Their Capacity to Support IgG-Secreting Cells in Culture Are Divergently Affected by Doxorubicin

  • Gintare Lasaviciute,
  • Anna Höbinger,
  • Dorina Ujvari,
  • Daniel Salamon,
  • Aisha Yusuf,
  • Mikael Sundin,
  • Eva Sverremark-Ekström,
  • Rayan Chikhi,
  • Anna Nilsson and
  • Shanie Saghafian-Hedengren

13 March 2021

Various subsets of bone marrow mesenchymal stromal cells (BM MSCs), including fibroblasts, endothelial, fat and reticular cells, are implicated in the regulation of the hematopoietic microenvironment and the survival of long-lived antibody-secreting...

  • Review
  • Open Access
3 Citations
5,086 Views
23 Pages

4 March 2021

The development of molecular studies to define the somatic genetic alterations has revolutionized the diagnostic and therapeutic management of acute myeloid leukemia (AML). AML is a highly heterogenous disease that includes many molecular subtypes; e...

  • Review
  • Open Access
3 Citations
5,043 Views
15 Pages

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates

  • Christie P. M. Verkleij,
  • Wassilis S. C. Bruins,
  • Sonja Zweegman and
  • Niels W. C. J. van de Donk

1 March 2021

In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care...

  • Commentary
  • Open Access
3,124 Views
13 Pages

28 February 2021

The story of Thomas Grogan, MD is one of the most compelling narratives in the modern history of pathology. Progressing from a quintessential academic pathologist to an entrepreneur and a renowned inventor, his remarkable journey is one of creativity...

  • Review
  • Open Access
1 Citations
2,757 Views
14 Pages

Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma

  • Benedetto Bruno,
  • Giuseppe Lia,
  • Francesca Bonifazi and
  • Luisa Giaccone

20 February 2021

Allogeneic hematopoietic cell transplantation in multiple myeloma has evolved over the decades. Myeloablative regimens have been replaced by the reduced intensity and non-myeloablative conditionings to reduce treatment-related toxicity and mortality...

  • Commentary
  • Open Access
1 Citations
3,958 Views
10 Pages

Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2

  • Jill Corre,
  • Michele Sabbah,
  • Fredrik Schjesvold,
  • Amer M. Zeidan,
  • Francesco Buccisano,
  • David Sallman,
  • Mario Mazzucato,
  • Leigh A. Madden,
  • Maurizio Martini and
  • Eric Van Breda
  • + 10 authors

9 February 2021

Recent Advancements in Hematology: Knowledge, Methods and Dissemination is a series of commentary article which is published on a biannual basis by the editorial board of the journal Hemato [...]

  • Review
  • Open Access
4 Citations
3,835 Views
15 Pages

15 January 2021

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality and is associated with high recurrence rates. The introduction of direct oral anticoagulants (DOACs) in the 2010s has changed the landscape of VTE management. DOACs have becom...

  • Review
  • Open Access
6 Citations
5,746 Views
21 Pages

2 January 2021

Impaired hematopoiesis is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Bone marrow aplasia and peripheral cytopenias arise from primary and secondary graft failure or primary and secondary poor graft fu...

  • Review
  • Open Access
10 Citations
12,982 Views
42 Pages

Why Immunotherapy Fails in Multiple Myeloma

  • Luis Gerardo Rodríguez-Lobato,
  • Aina Oliver-Caldés,
  • David F. Moreno,
  • Carlos Fernández de Larrea and
  • Joan Bladé

22 December 2020

Multiple myeloma remains an incurable disease despite great advances in its therapeutic landscape. Increasing evidence supports the belief that immune dysfunction plays an important role in the disease pathogenesis, progression, and drug resistance....

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Hemato - ISSN 2673-6357